An observational study in Aortic Valve Stenosis, sponsored by Prof. Dr. med. Ingo Eitel. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-03.
Sponsored by Prof. Dr. med. Ingo Eitel · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 191 studies in Aortic Valve Stenosis with a site in Germany — 39 open to participants now, 58 under way, 3 of them phase 3. Aortic Valve Stenosis · Germany.
Among the 191 studies in Aortic Valve Stenosis with a site in Germany, this one is the 12th largest by planned enrollment of the 98 observational ones that give a count, is one of 7 that started in 2025, is one of 98 observational ones, reaches primary completion later than 52 of the 57 other live ones, and was the 179th registered.
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
Browse Aortic Valve Stenosis studies →39 of the 191 studies in Aortic Valve Stenosis with a site in Germany are open now. Recruiting first, the newest first:
Erasmus Medical Center · Sites in Germany, Netherlands
Ages 70+
IHF GmbH - Institut für Herzinfarktforschung · Sites in Germany
Ages 18+
Idoven 1903 S.L. · Sites in Germany
Ages 18+ · Healthy volunteers
Institut für Pharmakologie und Präventive Medizin · Sites in Germany
Ages 18+
Ceric Sàrl · Sites in Germany, Austria, Estonia and 11 more countries
Ages 65–75
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
191 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,000 is above the median of 200 across 437 observational studies indexed under Aortic Valve Stenosis.
Median enrollment 220 across the 93 interventional studies, 300 across the 98 observational. Of the 109 that completed or were terminated, 28 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
93 of 191 have an industry lead sponsor. The 10 most frequent:
Prof. Dr. med. Ingo Eitel is the lead sponsor of 7 studies on the registry; 6 are open to participants now.
Prof. Dr. med. Ingo Eitel has 1 study filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
7 of the studies in Aortic Valve Stenosis with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07479992Idoven 1903 S.L.Multicenter Study for the Validation of Willem AI: Aortic StenoSis Early Diagnosis With AI-electrocardiogram Study | 2027-01 |
| NCT06493994University of LuebeckMyval TransAXillary Transcatheter Aortic Valve Replacement Multicenter Clinical Registry | 2027-01-30 |
| NCT05932615Abbott Medical DevicesENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2027-04 |
| NCT07520591Cardiawave SAValvosoft Outcomes Registry for Real-World Evidence | 2027-06-30 |
| NCT05603520Heinrich-Heine University, DuesseldorfPhenotyping Heterogeneity and Regionality of the Aorta | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 191 studies in Aortic Valve Stenosis with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Rational of the Myval THV - Prospective German Multicenter Registry is to evaluate the performance of this relatively new but very promising TAVR valve in a consecutive real-word, all-comers registry and to assess the long-term durability and efficacy of the Myval THV.
Patients who will be treated with Myval TAVR are included in the registry.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The Myval TAVR bioprothesis is a balloon-expandable THV developed by Meril Lifesciences, which has novel operator friendly design features to improve deliverability and aid precise deployment.
It is a composite of: - All-cause mortality - All stroke - Moderate or severe paravalvular regurgitation
Time frame: 5 Year
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2025 (actual). Primary completion is estimated for Dec 2030, 71 months after the start.
Of 206 non-industry observational studies under Aortic Valve Stenosis, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 120. This study's planned 71 months is above that.
Counting every sponsor, half of 243 studies reached it within 44 months; a quarter within 23 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Prof. Dr. med. Ingo Eitel